Piper Jaffray analyst Christopher Raymond raised his price target on Audentes Therapeutics to $45 and kept his Overweight rating, saying the company’s Q4 results were “uneventful”, but the next couple of quarters should be “anything but” given that the company’s AT132 is poised for a potential BLA in the near term. The analyst adds that the company’s unveiling of AT720 next quarter could also generate some excitement and sees Audentes Therapeutics’ current valuation as supported by its AT132 program and existing cash.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.